Deutsche Bank Boosts Price Target for Oxford Biomedica
Recently, on a Tuesday, it was reported that Oxford Biomedica (OXB:LN) (OTC: OXBDF) experienced a significant change in stock valuation as Deutsche Bank raised its price target. It increased from GBP2.50 to GBP3.80 while keeping a Hold rating on the stock. This adjustment comes on the heels of an exciting announcement from Oxford Biomedica regarding an impressive 18% increase in sales, totaling £51 million. This growth was fueled by new client acquisitions across the UK and contributions from its ABL acquisition, although it’s worth mentioning that the termination of an important contract in the US did hinder growth somewhat.
Reviewing the Financial Situation
In the latest financial report, Oxford Biomedica revealed an operating EBITDA loss of £20 million, primarily due to strategic investments aimed at preparing the company for an anticipated surge in demand later this year. Despite facing this loss, Oxford Biomedica finished the reporting period with a solid net cash position of £42 million. For fiscal year 2024, the company has kept its revenue guidance unchanged, expecting figures to fall between £124 million and £136 million.
Promising Mid-Term Outlook
The mid-term outlook for Oxford Biomedica appears bright, supported by a contracted order book currently valued at £94 million and a substantial backlog of £120 million, which provides visibility extending well into 2025. The company continues to project a low-double-digit operating EBITDA loss for the year, suggesting a possible swing back to profitability or at least a breakeven point in the latter half of the year.
Deutsche Bank Adjusts Revenue Projections
Considering all these aspects, Deutsche Bank has reassessed its revenue forecast for Oxford Biomedica for fiscal year 2024, now estimating it will reach £127 million. This projection places them at the lower end of the previously stated guidance range. The revised price target reflects a sentiment of cautious optimism regarding Oxford Biomedica's financial future, especially in relation to the expected demand for its services in the rapidly growing cell and gene therapy sector.
Frequently Asked Questions
What caused the increase in Oxford Biomedica's price target?
Deutsche Bank raised the price target to GBP3.80 due to an 18% increase in sales reported by Oxford Biomedica.
What sales figures did Oxford Biomedica report?
The company reported total sales of £51 million during their recent reporting period.
What is the financial outlook for Oxford Biomedica in fiscal year 2024?
Oxford Biomedica is maintaining its revenue expectation, anticipating figures between £124 million and £136 million for FY 2024.
How much cash is Oxford Biomedica currently holding?
According to the latest report, the company has a strong net cash position of £42 million.
What is the expected demand for Oxford Biomedica's services?
The demand for services in the cell and gene therapy sector is projected to remain strong, positively affecting future growth and revenues.
